Epidemiology and spectrum of disease of Escherichia coli O157

Current Opinion in Infectious Diseases

Volumn 16, Issue 3, 2003, Pages 259-263

  Ochoa, Theresa J ^a   Cleary, Thomas G ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Hemolytic uremic syndrome; Microangiopathic hemolytic anemia; Shiga toxin producing E. coli

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; SHIGA TOXIN;

BLOOD CLOTTING DISORDER; CELL SWELLING; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; EARLY DIAGNOSIS; ENDOTHELIUM CELL; ENTEROBACTER INFECTION; ENZYME IMMUNOASSAY; ESCHERICHIA COLI O157; FECES CULTURE; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; LATEX AGGLUTINATION TEST; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; THROMBOTIC THROMBOCYTOPENIC PURPURA; THROMBUS;

EID: 0038282399     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200306000-00013     Document Type: Review

References (63)

1. Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186:493-500. This was a very large (394 children with HUS) study of STEC in Europe. Its results are useful for comparisons with US and other data.
2. Elliott EJ, Robins-Browne RM, O'Loughlin EV, et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 2001; 85:125-131.
3. Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183:1063-1070.
4. Ludwig K, Sarkim V, Bitzan M, et al. Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome. J Clin Microbiol 2002; 40:1773-1782. This paper confirms the data on the high frequency of toxin associated disease in families of children with HUS. It further suggests the importance of the idea that B subunit specific antibodies might have a protective role.
5. Kravitz GR, Smith K, Wagstrom L. Colonic necrosis and perforation secondary to Escherichia coli O157:H7 gastroenteritis in an adult patient without hemolytic uremic syndrome. Clin Infect Dis 2002; 35:E103-E105.
6. Shigeno T, Akamatsu T, Fujimori K, et al. The clinical significance of colonoscopy in hemorrhagic colitis due to enterohemorrhagic Escherichia coli O157:H7 infection. Endoscopy 2002; 34:311-314.
7. Brandt JR, Joseph MW, Fouser LS, et al. Cholelithiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Nephrol 1998; 12:222-225.
8. Wall PG, McDonnell RJ, Adak GK, et al. General outbreaks of vero cytotoxin producing Escherichia coli O157 in England and Wales from 1992 to 1994. Commun Dis Rep CDR Rev 1996; 6:R26-R33.
9. Orr P, Lorencz B, Brown R, et al. An outbreak of diarrhea due to verotoxin-producing Escherichia coli in the Canadian Northwest Territories. Scand J Infect Dis 1994; 26:675-684.
10. Bell BP, Goldoft M, Griffin PM, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994; 272:1349-1353.
11. Fukushima H, Hashizume T, Morita Y, et al. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Pediatr Int 1999; 41:213-217.
12. Klein EJ, Stapp JR, Clausen CR, et al. Shiga toxin-producing Escherichia coli in children with diarrhea: A prospective point-of-care study. J Pediatr 2002; 141:172-177.
13. Lopez EL, Contrini MM, Devoto S, et al. Incomplete hemolytic-uremic syndrome in Argentinean children with bloody diarrhea. J Pediatr 1995; 127:364-367.
14. Dundas S, Todd WT, Stewart AI, et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33:923-931.
15. Wood R, Donaghy M, Dundas S. Monitoring patients in the community with suspected Escherichia coli O157 infection during a large outbreak in Scotland in 1996. Epidemiol Infect 2001; 127:413-420.
16. Buteau C, Proulx F, Chaibou M, et al. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J 2000; 19:642-647.
17. Kawamura N, Yamazaki T, Tamai H. Risk factors for the development of Escherichia coli O157:H7 associated with hemolytic uremic syndrome. Pediatr Int 1999; 41:218-222.
18. Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100(1)E12:1-6.
19. Ikeda K, Ida O, Kimoto K, et al. Predictors for the development of haemolytic uraemic syndrome with Escherichia coli O157:H7 infections: with focus on the day of illness. Epidemiol Infect 2000; 124:343-349.
20. Hancock D, Besser T, Lejeune J, et al. The control of VTEC in the animal reservoir. Int J Food Microbiol 2001; 66:71-78.
21. Meyer-Broseta S, Bastian SN, Arne PD, et al. Review of epidemiological surveys on the prevalence of contamination of healthy cattle with Escherichia coli serogroup O157:H7. Int J Hyg Environ Health 2001; 203:347-361. This review analyzes the 26 published epidemiological surveys that have evaluated the prevalence of STEC O157:H7 infection of cows. Studies from both Europe and North America were included. It is a nice summary of risk factors during all the events from farm to fork. Areas that need more investigation are highlighted. This paper is a good starting point for those interested in understanding the complexity of industrial scale beef production and its implications for infectious diseases.
22. Ogden ID, Hepburn NF, MacRae M, et al. Long-term survival of Escherichia coli O157 on pasture following an outbreak associated with sheep at a scout camp. Lett Appl Microbiol 2002; 34:100-104.
23. Johnsen G, Wasteson Y, Heir E, et al. Escherichia coli O157:H7 in faeces from cattle, sheep and pigs in the southwest part of Norway during 1998 and 1999. Int J Food Microbiol 2001; 65:193-200.
24. Licence K, Oates KR, Synge BA, Reid TM. An outbreak of E. coli O157 infection with evidence of spread from animals to man through contamination of a private water supply. Epidemiol Infect 2001; 126:135-138.
25. Renter DG, Sargeant JM, Hygnstorm SE, et al. Escherichia coli O157:H7 in free-ranging deer in Nebraska. J Wildl Dis 2001; 37:755-760.
26. Olsen SJ, Miller G, Kennedy M, et al. A waterborne outbreak of Escherichia coli O157:H7 infections and hemolytic uremic syndrome: implications for rural water systems. Emerg Infect Dis 2002; 8:370-375.
27. Rabatsky-Ehr T, Dingman D, Marcus R, et al. Deer meat as the source for a sporadic case of Escherichia coli O157:H7 infection, Connecticut. Emerg Infect Dis 2002; 8:525-527.
28. From the Centers for Disease Control. Outbreak of Escherichia coli O157:H7 infection associated with eating fresh cheese curds: Wisconsin, June 1998, JAMA 2000; 284:2991-2992.
29. Mohle-Boetani JC, Farrar JA, Werner SB, et al. Escherichia coli O157 and Salmonella infections associated with sprouts in California, 1996-1998. Ann Intern Med 2001; 135:239-247.
30. te Loo DM, Heuvelink AE, de Boer E, et al. Vero cytotoxin binding to polymorphonuclear leukocytes among households with children with hemolytic uremic syndrome. J Infect Dis 2001; 184:446-450.
31. Heuvelink AE, van Heerwaarden C, Zwartkruis-Nahuis JT, et al. Escherichia coli O157 infection associated with a petting zoo. Epidemiol Infect 2002; 129:295-302.
32. Outbreaks of Escherichia coli O157:HT infections among children associated with farm visits: Pennsylvania and Washington, 2000. Can Commun Dis Rep 2001; 27:117-120.
33. Crump JA, Sulka AC, Langer AJ, et al. An outbreak of Escherichia coli O157:H7 infections among visitors to a dairy farm. N Engl J Med 2002; 347:555-560.
34. Samadpour M, Stewart J, Steingart K, et al. Laboratory investigation of an E. coli O157:H7 outbreak associated with swimming in Battle Ground Lake, Vancouver, Washington. J Environ Health 2002; 64:16-20, 26, 25.
35. Bertin Y, Boukhors K, Pradel N, et al. Stx2 subtyping of Shiga toxin-producing Escherichia coli isolated from cattle in France: detection of a new Stx2 subtype and correlation with additional virulence factors. J Clin Microbiol 2001; 39:3060-3065.
36. Friedrich AW, Bielaszewska M, Zhang WL, et al. Escherichia coli harboring Shiga toxin 2 gene vanants: frequency and association with clinical symptoms. J Infect Dis 2002; 185:74-84. This describes the clearest and most definitive data regarding the relative importance of the various Stx types.
37. Zhang W, Bielaszewska M, Kuczius T, Karch H. Identification, characterization, and distribution of a Shiga toxin 1 gene variant (stx(1c)) in Escherichia coli strains isolated from humans. J Clin Microbiol 2002; 40:1441-1446. This study is important because it helped to define the source and significance of a major variant of Stx1.
38. Paton AW, Paton JC. Direct detection and characterization of Shiga toxigenic Escherichia coli by multiplex PCR for stx1, stx2, eae, ehxA, and saa. J Clin Microbiol 2002; 40:271-274.
39. Chaisri U, Nagata M, Kurazono H, et al. Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome. Microb Pathog 2001; 31:59-67.
40. Proulx F, Seidman EG, Karpman D. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res 2001; 50:163-171.
41. Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic-uremic syndrome. Semin Thromb Hemost 2001; 27:207-213.
42. Ohmi K, Kiyokawa N, Takeda T, Fujimoto J. Human microvascular endothelial cells are strongly sensitive to Shiga toxins. Biochem Biophys Res Commun 1998; 251:137-141.
43. Keusch GT, Acheson DW, Aaldering L, et al. Comparison of the effects of Shiga-like toxin 1 on cytokine- and butyrate-treated human umbilical and saphenous vein endothelial cells. J Infect Dis 1996; 173:1164-1170.
44. Uchida H, Kiyokawa N, Horie H, et al. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome. Pediatr Res 1999; 45:133-137.
45. Andreoli SP, Trachtman H, Acheson DW, et al. Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol 2002; 17:293-298. This is an excellent recent review of the current state of the STEC/HUS art.
46. Siegler RL, Pysher TJ, Tesh VL, Taylor FB. Renal prostacyclin biosynthesis in a baboon model of shiga toxin mediated hemolytic uremic syndrome. Nephron 2002; 92:363-368. This is one of a series of incredibly important studies using the baboon model. Although this model does not address issues at the gut level, it is by far the best model for study of the endothelial and renal injury events. It seems to very closely parallel the human disease.
47. Pysher TJ, Siegler RL, Tesh VL, Taylor FB. von Willebrand Factor Expression in a Shiga Toxin-mediated Primate Model of Hemolytic Uremic Syndrome. Pediatr Dev Pathol 2002; 5:5. The role of von Willebrand Factor has been debated extensively because the data have been conflicting. This study using the baboon model strongly suggested that systemic release of von Willebrand Factor is not central to pathogenesis.
48. Litalien C, Proulx F, Mariscalco MM, et al. Circulating inflammatory cytokine levels in hemolytic uremic syndrome. Pediatr Nephrol 1999; 13:840-845.
49. Proulx F, Toledano B, Phan V, et al. Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. Pediatr Res 2002; 52:928-934.
50. Grabowski EF. The hemolytic-uremic syndrome-toxin, thrombin, and thrombosis. N Engl J Med 2002; 346:58-61. This is an excellent editorial summarizing current opinion regarding the coagulopathy of HUS.
51. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346:23-32. Although the definition of HUS used is problematic (it is likely to include children who do not actually have HUS), the main findings in this prospective study are critically important to our understanding of pathogenesis. Both impaired fibrinolysis and thrombin generation precede development of HUS.
52. Tsai HM, Chandler WL, Sarode R, et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:HT-associated hemolytic uremic syndrome. Pediatr Res 2001; 49:653-659.
53. Hunt BJ, Lammle B, Nevard CH, et al. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001; 85:975-978.
54. Ray P, Acheson D, Chitrakar R, et al. Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. J Am Soc Nephrol 2002; 13:699-707.
55. Park CH, Kim HJ, Hixon DL. Importance of testing stool specimens for shiga toxins. J Clin Microbiol 2002; 40:3542-3543.
56. Kehl SC. Role of the laboratory in the diagnosis of enterohemorrhagic Escherichia coli Infections. J Clin Microbiol 2002; 40:2711-2715. This excellent review summarizes both the history of development of diagnostic tests and the current state of the art. The rationale for testing as well as the data supporting use of each method are presented.
57. Reischl U, Youssef MT, Kilwinski J, et al. Real-time fluorescence PCR assays for detection and characterization of Shiga toxin, intimin, and enterohemolysin genes from Shiga toxin-producing Escherichia coli. J Clin Microbiol 2002; 40:2555-2565.
58. Paton JC, Paton AW. Methods for detection of STEC in humans. An overview. Methods Mol Med 2003; 73:9-26.
59. Paton AW, Paton JC. Detection and characterization of STEC in stool samples using PCR. Methods Mol Med 2003; 73:45-54.
60. Cornick NA, Jelacic S, Ciol MA, Tarr PI. Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome. J Infect Dis 2002; 186:57-63. This paper suggests that therapeutic strategies aimed at removal of toxin from gut may be futile.
61. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichla coli O157:H7 infections. N Engl J Med 2000; 342:1930-1936.
62. Ohara T, Kojio S, Taneike I, et al. Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 2002; 46:3478-3483. This report raises the possibility that antibiotic therapy might both decrease toxin production and inflammatory cytokine responses. Unfortunately there are no data in humans to confirm this phenomenon where it is most relevant.
63. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002; 288:996-1001.